ISSN 2149-3235 | E-ISSN 2149-3057
Original Article
Adrenocortical carcinoma: Single center experience
1 Clinic of Endocrinology and Metabolism, Harakani State Hospital, Kars, Turkey  
2 Department of Internal Medicine, Uludağ University School of Medicine, Bursa, Turkey  
3 Clinic of Endocrinology and Metabolism, Yusuf İslamoğlu State Hospital, Kastamonu, Turkey  
4 Department of Endocrinology and Metabolism, Uludağ University School of Medicine, Bursa, Turkey  
Turk J Urol 2017; 43: 462-469
DOI: 10.5152/tud.2017.81598
Key Words: Adrenocortical carcinoma; chemotherapy; mitotane; surgery
Abstract

Objective: Adrenocortical carcinoma is an aggressive endocrine malignancy with an annual incidence of 0.5-2 cases per million. The most important factors that determine prognosis are tumor stage at the time of diagnosis and the success of surgery. However, advanced age, large tumor size, hormone secretion, high Ki-67 index (>10%), tumor necrosis and high mitotic activity are other factors associated with poor prognosis. In the present study, we aimed to evaluate the contribution of the patient and treatment- related factors to the prognosis in adrenocortical carcinoma.

 

Material and methods: We included 15 adrenocortical carcinoma patients who were followed in our center between 2005 and 2015. The effects of age, gender, tumor size, type of operation, postoperative resection status and adjuvant treatment on disease-free survival and overall survival were analyzed.

 

Results: Disease-free survival was 23.32±3.69 months and overall survival was 36.60±10.78 months. Gender, tumor size, tumor stage, type of operation, hormonal activity, presence of necrosis, recurrence and development of metastasis were not found to be associated with disease-free survival and overall survival. Postoperatively applied adjuvant treatments including mitotane, chemotherapy and radiotherapy did not significantly affect disease-free survival in our study, but statistically significant increase in overall survival was observed in patients getting adjuvant treatments.

 

 

Conclusion: Adrenocortical carcinoma has poor prognosis and short overall survival, and in its clinical course, recurrence and development of metastasis can be commonly observed even after complete resection of the tumor. Therefore, the patients should be evaluated carefully while determining the surgical procedure during the preoperative period, and the operation and post-operative follow-up should be performed in experienced centers. However, due to the positive effects of adjuvant treatments on survival, all patients should be evaluated postoperatively for the necessity of adjuvant treatments, especially mitotane.

 

 

Cite this article as: Şişman P, Şahin AB, Peynirci H, Cander S, Öz Gül Ö, Ertürk E, et al. Adrenocortical carcinoma: Single center experience. Turk J Urol 2017; 43(4): 462-9

Key Words
Authors
All
Survey
AVES | Copyright © 2018 Turkish Association of Urology | Latest Update: 13.06.2018